News

JDRF funded collaboration with UCLA on Type 1 Diabetes

End of June 2016 Algiax started a collaboration program to perform a preclinical Proof-of-Concept in Diabetes Type 1 with a selection of Algiax` proprietary new chemical entities.

Clinical Phase Ib, Pharmacodynamic effect study

On December 10th 2015 Algiax got its approval from the German authorities (BfArM) to start the Phase Ib study entitled “Pharmacodynamic Effects of AP-325 in Healthy Male Subjects using the Intradermal (ID) Capsaicin and Pressure Pain Models”.

Algiax announces positive data of Clinical Phase I

Today Algiax announces the completion of two successful Phase I trials with their lead compound AP-325. AP-325 was tested in both single and multiple dose studies in healthy volunteers. In the two clinical studies AP-325 was shown to be safe and well tolerated and the aimed exposure levels with the oral formulation have been reached.

Clinical Phase Ia, multiple ascending dose

As of June 2015, Algiax initiated a Phase I study with the primary objective to investigate the pharmacokinetics, safety, and tolerability of multiple ascending doses of AP-325 in healthy male subjects.

Clinical Phase Ia, single dose

As of November 2014, Algiax initiated a Phase I study with the primary objective to investigate the pharmacokinetics, safety, and tolerability of single ascending doses of AP-325 in healthy male subjects. In addition, Algiax aimed to investigate the influence of food, gender and age on the safety, tolerability, and pharmacokinetics of a single oral dose of AP-325.

Orphan Drug Designation

In August 2013 our lead compound AP-325 received Orphan Drug Designation from EMA for the treatment of traumatic spinal cord injury.

Series A investment

In January 2012 a Series A investment of 4.3M€ was closed.